CRMD — CorMedix Inc. Stock Price, Chart & AI Report

Positive Dec 24, 2025 • 08:42 UTC Investing.com • Nathan Reiff

CorMedix Builds a Real Revenue Story as DefenCath Adoption Accelerates

CorMedix is experiencing strong commercial momentum with its DefenCath catheter lock solution, which has shown a 72% reduction in catheter-related bloodstream infections in real-world evidence studies. The company reported Q3 2025 net revenue of $104.3 million and raised full-year guidance to $390-410 million. DefenCath adoption is outpacing expectations, and the Melinta Therapeutics acquisition adds diversification. Analysts are optimistic with nearly-unanimous Buy ratings and see 48% upside potential, though risks include pricing pressure and pipeline concentration.

CRMD DefenCath catheter lock solution dialysis infections real-world evidence commercial adoption Melinta Therapeutics acquisition REZZAYO

Sentiment note

Strong commercial execution with DefenCath adoption exceeding targets, significant revenue growth ($104.3M Q3 2025), raised full-year guidance, impressive adjusted EBITDA improvement ($72M vs -$2M prior year), strategic acquisition of Melinta adding revenue diversification, nearly-unanimous Wall Street Buy ratings, and promising Phase III pipeline data expected in Q2 2026. Stock has already gained 51% YTD with analysts seeing 48% additional upside.

Neutral Nov 21, 2025 • 14:00 UTC GlobeNewswire Inc. • Lavarne A. Burton

American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative Solutions

The American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.

CRMD TVTX kidney disease AI healthcare innovation patient access early detection

Sentiment note

Mentioned as a Leadership Sponsor with no specific details about performance or impact

Positive Nov 12, 2025 • 16:00 UTC GlobeNewswire Inc. • Na

Strong Earnings and Biotech Resilience Define the Midweek Momentum

Several biotech companies reported significant developments, including Kraig Labs' breakthrough in spider silk production, Salarius Pharmaceuticals' public offering, Humacyte's Q3 progress, and CorMedix's record quarterly earnings.

KBLB SLRX HUMA HUMAW biotechnology spider silk medical innovation financial performance

Sentiment note

Reported record Q3 revenue of $104.3 million, significant net income increase, and raised full-year guidance

Positive Sep 29, 2025 • 12:30 UTC Benzinga • Globe Newswire

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

CorMedix completed enrollment in a Phase III clinical trial for REZZAYO, a drug aimed at preventing fungal infections in patients undergoing blood and marrow transplantation. Topline results are expected in Q2 2026, with potential FDA approval for prophylaxis treatment.

CRMD clinical trial fungal infection drug development BMT prophylaxis

Sentiment note

Completed clinical trial enrollment, advancing drug development, potential significant market opportunity with estimated $2B addressable market

Positive Sep 2, 2025 • 11:30 UTC Benzinga • Globe Newswire

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

CorMedix has successfully acquired Melinta Therapeutics for $300 million, expanding its commercial product portfolio with seven innovative drug products and raising financial guidance to $325-$350 million in pro forma 2025 revenues.

CRMD acquisition pharmaceutical merger healthcare biotech

Sentiment note

Company completed a transformational acquisition that diversifies its product portfolio, increases revenue potential, and is expected to be accretive to earnings with projected synergies of $35-$45 million

Neutral Dec 10, 2024 • 07:45 UTC GlobeNewswire Inc. • Polaris Market Research

Closed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMR

The global closed system transfer device market is projected to grow from $1.1 billion in 2024 to $4.8 billion by 2034, driven by advancements in technology and increasing cancer cases worldwide.

BAX CRMD ICUI closed system transfer device healthcare cancer chemotherapy occupational safety

Sentiment note

The article mentions Cormed as one of the key players in the closed system transfer device market, but does not provide any specific information about the company's performance or outlook.

Positive Sep 9, 2024 • 20:06 UTC Benzinga • Zacks

Here's Why CorMedix Is a Great 'Buy the Bottom' Stock Now

CorMedix (CRMD) stock has been struggling, but a hammer chart pattern and strong earnings estimate revisions suggest a potential trend reversal. The article highlights the technical and fundamental factors that make CRMD a good 'buy the bottom' stock.

CRMD CorMedix stock technical analysis earnings estimate revisions

Sentiment note

The article suggests that CorMedix is a good 'buy the bottom' stock due to a hammer chart pattern, which indicates a potential trend reversal, and strong earnings estimate revisions, which are a bullish fundamental indicator.

Positive Sep 9, 2024 • 14:52 UTC GlobeNewswire Inc. • N/A

CorMedix Inc. Announces New Commercial Agreement

CorMedix Inc. has entered into a multi-year commercial supply contract with a global healthcare company for the supply of its approved product DefenCath, which is used to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis.

CRMD CorMedix DefenCath commercial supply contract healthcare company catheter-related bloodstream infections

Sentiment note

The article highlights CorMedix's progress in commercializing its approved product DefenCath, including entering into a multi-year supply contract with a major healthcare provider, which indicates the company's ability to successfully bring its product to market and secure significant commercial partnerships.

Unknown Jun 6, 2024 • 12:30 UTC GlobeNewswire Inc. • CorMedix, Inc.

CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath

BERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS). Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the out-patient ambulatory setting for a period of at least two years, and up to a maximum of three years.

CRMD Product / Services Announcement

Unknown May 9, 2024 • 15:00 UTC The Motley Fool • newsfeedback@fool.com (Motley Fool Transcribing)

CorMedix (CRMD) Q1 2024 Earnings Call Transcript

CRMD earnings call for the period ending March 31, 2024.

CRMD earningscall-transcripts

Unknown May 9, 2024 • 11:30 UTC GlobeNewswire Inc. • CorMedix, Inc.

CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

CRMD Earnings Releases and Operating Results

Unknown May 2, 2024 • 13:55 UTC Zacks Investment Research • Zacks Equity Research

Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?

The mean of analysts' price targets for CorMedix (CRMD) points to a 135.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CRMD